The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 66 | 3.2x | 20.1x | Near average | |
Growth | 83 | 13.7% | 5.6% | Above average | |
Quality | 81 | 18.3% | 7.6% | Above average | |
Safety | 77 | -1.6x | 0.4x | Above average | |
Capital Return | 38 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Innoviva stock shows a state of complete stability in analyst estimates over the short and medium terms (1, 7, and 30 days), as the average price target settled at $40 without any significant adjustments. This consistency reflects a firm conviction among the three analysts covering the stock, despite a notable price gap between the low ($32) and the high ($46), indicating a divergence in the fair value estimation of the company's core assets.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Innoviva, Inc. (NASDAQ: INVA) is a leading healthcare and drug development company, focusing primarily on managing investment portfolios of pharmaceutical assets and royalty revenues associated with respiratory and other medications. The company generates its revenues mainly through royalty revenues and agreements with major global pharmaceutical companies, in addition to strategic acquisitions and the development of hospital anti-infectives.
In the first quarter of 2026, the company's financial results showed a strong performance, with total revenues reaching $98.0 million and a gross profit of $75.8 million. The company also recorded an exceptional net income of $186.6 million, which reflected positively on earnings per share, reaching $2.22 during this quarter, demonstrating high operational efficiency and the ability to achieve high profit margins compared to the volume of direct operational revenues.
These strong results for the first quarter of 2026 follow an outstanding fourth quarter at the end of 2025 (FY 2025), where the company recorded revenues of $411.3 million, a gross profit of $307.7 million, and a net income of $271.2 million, with earnings per share of $3.3. This seasonal variation and structural growth show the resilience of Innoviva's investment portfolio and its ability to generate sustainable cash flows from its royalty assets.
The stock is currently trading at $21.7, which is below the average analyst target of $40 (84.3%), with a buy consensus.
In the first quarter of 2026, Innoviva reported revenues of $98.0 million, with a gross profit of $75.8 million. The company also recorded a very strong net income of $186.6 million, resulting in earnings per share (EPS) of $2.22 during this quarter.
Analysts consensus is a 'Buy' recommendation for Innoviva (INVA) stock, with an average target price of $40.0. Analyst estimates range between a high of $46.0 and a low estimated at $32.0, which means that the current price of $21.7 trades significantly below these targets.
Innoviva ended 2025 with a very strong financial performance in the fourth quarter, recording revenues of $411.3 million and a gross profit of $307.7 million. Net income for that period reached $271.2 million, which was reflected in earnings per share of $3.3 for the full fiscal year.
Automated analysis for informational purposes only — not investment advice.
On May 28, 2026, BTIG analysts issued positive evaluations and ratings for Innoviva (INVA) alongside other healthcare companies such as MDAI and NTHI. These positive recommendations came to mitigate the impact of the news issued on May 7, 2026, which pointed to mixed earnings results for US mid- and small-cap companies.